NCT07090161 Phase 2 Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Study sponsor: Vanda Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-10 Estimated
Enrollment · participants 240 Estimated
Source updated 2026-02-27 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-12-02 · 1 field changed
Recruitment status changed
− Before Not yet recruiting
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology